Novartis Net Profit Boosted by Gain From Sandoz Spinoff
By Adria Calatayud
Novartis reported a big jump in fourth-quarter net profit after it booked a gain from the spinoff of its generics-drugs business Sandoz.
Net profit for the fourth quarter was $8.48 billion compared with $1.47 billion in the same period a year before, the Swiss pharmaceutical major said Wednesday. This included a non-cash gain of $5.9 billion from the distribution of Sandoz shares to Novartis shareholders, it said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
January 31, 2024 01:28 ET (06:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
After Earnings, Is MongoDB Stock a Buy, a Sell, or Fairly Valued?
-
Where We See Opportunities in June as Stocks Recover Losses
-
10 Top-Performing Dividend Stocks of the Month
-
10 Cheap Dividend-Growth Stocks to Buy
-
Manager: Nvidia Will Be Biggest Company in the World
-
The Best Utilities Stocks to Buy
-
3 Cheap Dividend Stocks to Buy Yielding 4% or More
-
After Earnings, Is Salesforce Stock a Buy, Sell, or Fairly Valued?